The study sought to determine the costs of liver transplantation in Turkey. All costs except physician charges were retrospectively investigated in the period from hospitalization to discharge. Liver transplantation was performed in 326 patients between 1999 and 2009. After exclusion of patients whose records could not be accessed (n=5), who underwent second transplantations in the same hospitalization (n=3) or who died before discharge (n=39), 279 patients were eligible for the study. The mean cost of liver transplantation was 30.823 dollars. The mean cost in 2008 was significantly higher than for all other years; thereafter it decreased. Costs were shown to be higher among patients with model for end-stage liver disease (MELD) scores>15. Although there was no significant cost difference among United Network for Organ Sharing (UNOS) groups, the mean costs of subjects of the B group were significantly lower than those of the Child C subjects C (P=.01). When we evaluated the relationship between etiological groups and costs the highest expenses were noted among hepatitis B virus (HBV) and hepato cellular carcinoma (HCC) patients with 75% HBV-positivity together. There was no significant difference between age, gender, and body mass index (BMI) of recipients. The costs did not significantly change with the presence of diabetes mellitus (DM) or portal vein thrombosis before transplantation or antibiotic use after transplantation. Although there was no difference between donor age and costs, living donor transplantation showed significantly higher costs than cadaveric donor cases (P=.01). In conclusion, liver transplantation is an effective treatment in end-stage liver diseases with high cost, albeit in Turkey it is relatively lower than other countries.
Copyright © 2011 Elsevier Inc. All rights reserved.